ADMINISTRATION OF PHLEBOTROPIC DRUGS DURING COMPLEX TREATMENT OF ACUTE HEMORRHOIDS

OBJECTIVES OF RESEARCH. To assess the clinical effectiveness of phlebotrophic drug Detralex (Micronized purifiedflavonoid fraction (MPFF)) during complex treatment of patients with acute hemorrhoids. MATERIALS AND METHODS. A comparative analysis of treatment outcomes of 293 patients with acute hemorrhoids was conducted. All patients were divided into two groups for further clinical observations. Standard drug therapy was performedfor 145 patients (group I). For 148 patients (group II), in addition to the standard treatment, phlebotrophic drug Detralex was additionally initiated. Research program included detection of content of acute inflammatory phase reactants and pro-inflammatory cytokines in blood plasma, evaluation of pain syndrome severity (VRS) and quality of life parameters (SF-36 questionnaire). RESULTS. Initiation of MPFF with complex treatment of patients with acute hemorrhoids was found to be contributed to faster elimination of edema and inflammation, a decrease in severity of hemorrhoids thrombosis, relief of pain syndrome and improvement in patients'quality of life, along withwell-marked regression of laboratory markers of inflammatory reaction This allows to increase the number of good outcomes of acute hemorrhoids treatment from 66,2% to 89,9%, that is by 23,7% and to reduce the number of unsatisfactory outcomes from 4,2% to 1,3%, that is by 2,9%. CONCLUSION. Inclusion of Detralex into program of acute hemorrhoids treatment contributes to a faster elimination of clinical and laboratory manifestations of the disease and allows improving the results of treatment for this category of patients.